JNJ 17216498

Drug Profile

JNJ 17216498

Alternative Names: JNJ-17216498

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Sleep disorder therapies
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Narcolepsy

Most Recent Events

  • 30 Nov 2006 Phase-II clinical trials in Narcolepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top